Effect of a nonpepf ide vasopressin v1 antagonist (OPC-21268) on experimental accelerated focal glomerulosclerosis

Isao Kurihara, Takao Saito, Katsuya Ohara, Yoshiharu Shoji, Mariko Hirai, Jun Soma, Hiroshi Sato, Yutaka Imai, Keishi Abe

研究成果: Article査読

22 被引用数 (Scopus)

抄録

The effects of the nonpeptide orally effective vasopressin V1 receptor antagonist OPC-21268 were studied in progressive focal glomerulosclerosis (FGS) which developed in spontaneously hypercholesterolemic (SHC) rats with manifestations of hypercholesterolemia and proteinuria. Unilateral nephrectomy was performed at 7 weeks of age to accelerate spontaneous FGS. After nephrectomy, OPC-administered rats were fed chow containing 1% OPC-21268 for 9 weeks. Treatment with vasopressin V1 antagonist significantly reduced the rate of increase in the levels of triglyceride, systolic blood pressure, serum creatinine and BUN, and prevented a significant deterioration in creatinine clearance. Rats were sacrificed at 16 weeks of age. Histologically, the index of glomerular sclerosis in the OPC group showed a significant decrease compared to that in the control group (2.2 ± 0.1 vs. 2.6 ± 0.1, p < 0.01). Relative interstitial volume and glomerular volume in the OPC group showed a tendency to decrease compared to those in the control group. These results indicate that vasopressin plays an important role through V1 receptors in the development of glomerulosclerosis, and vasopressin V1 antagonist may prevent the progression of renal injury in glomerulosclerosis.ic epitopes.

本文言語English
ページ(範囲)629-636
ページ数8
ジャーナルNephron
73
4
DOI
出版ステータスPublished - 1996

ASJC Scopus subject areas

  • 生理学
  • 腎臓病学
  • 生理学(医学)
  • 泌尿器学

フィンガープリント

「Effect of a nonpepf ide vasopressin v1 antagonist (OPC-21268) on experimental accelerated focal glomerulosclerosis」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル